A randomized discontinuation phase II trial of ridaforolimus in non-small cell lung cancer (NSCLC) patients with KRAS mutations.

Gregory J. Riely, Rafael Rosell, Julie R. Brahmer et al.|Journal of Clinical Oncology|2012

Cited by 42